A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Washington Post National Health Reporter Paige Winfield Cunningham discusses how the Trump administration is considering ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Revenue reached $67.2 billion, beating analyst estimates by 7.3% (non-GAAP) and growing 11% year over year. Adjusted earnings per share (EPS) rose to $7.20, surpassing expectations and EPS increased 7 ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, ...